In OncLive® On Air, you can expect to hear interviews with academic oncologists on the thought-provoking oncology presentations they give at the OncLive® State of the Science Summits. The topics in oncology vary, from systemic therapies, surgery, radiation therapy, to emerging therapeutic approaches in a particular type of cancer. This includes lung cancer, breast cancer, gastrointestinal cancers, hematologic malignancies, gynecologic cancers, genitourinary cancers, and more.
…
continue reading
1
S10 Ep26: Lunning and Rutherford Detail Considerations for BV-AVD Use in Older Patients With Hodgkin Lymphoma
13:31
13:31
「あとで再生する」
「あとで再生する」
リスト
気に入り
気に入った
13:31
Drs Lunning and Rutherford discuss findings from the ECHELON-1 trial of BV-AVD in the cohort of patients with Hodgkin lymphoma over 60 years of age.OncLive® On Air による
…
continue reading
1
S10 Ep25: Breast Cancer Experts Share Obstacles and Successes as Women in Oncology
42:16
42:16
「あとで再生する」
「あとで再生する」
リスト
気に入り
気に入った
42:16
Drs Graff, Mahtani, McCann, and Rugo shared moments throughout their lives and careers that sparked their interest in oncology, setbacks they overcame when building their careers, obstacles they encounter as women in the field, and ways that gender bias can be confronted at both the individual and institutional levels.…
…
continue reading
1
S1 Ep18: FDA Approval Insights: Ponatinib in Ph+ ALL
9:19
9:19
「あとで再生する」
「あとで再生する」
リスト
気に入り
気に入った
9:19
Dr Jabbour expands on the multiple milestones achieved through ponatinib’s FDA approval for patients with Ph-positive ALL; the agent’s potency and unique mechanism of action; and key efficacy and safety data from the PhALLCON trial supporting this regulatory decision.OncLive® On Air による
…
continue reading
1
S10 Ep24: Schmid Summarizes Updates in HER2-Positive Breast Cancer Management
14:04
14:04
「あとで再生する」
「あとで再生する」
リスト
気に入り
気に入った
14:04
Dr Schmid discusses considerations for applying recent data updates in HER2-positive breast cancer management to clinical practice.OncLive® On Air による
…
continue reading
1
S10 Ep23: Wagner on the Investigation of Nab-Sirolimus in Advanced Malignant PEComa
15:07
15:07
「あとで再生する」
「あとで再生する」
リスト
気に入り
気に入った
15:07
Dr Wagner discusses current unmet needs for patients with PEComa, how ongoing research aims to address some of these gaps, and how findings from the AMPECT trial in particular support the use of nab-sirolimus in patients with advanced malignant disease.OncLive® On Air による
…
continue reading
1
S10 Ep22: CRC Experts Highlight AE Management and Prevention Strategies for TAS-102/Bevacizumab, Regorafenib, and Fruquintinib
35:25
35:25
「あとで再生する」
「あとで再生する」
リスト
気に入り
気に入った
35:25
Strickler, Leung, Dasari, and O'Neill discuss adverse effect monitoring and management with standard agents for patients with colorectal cancer.OncLive® On Air による
…
continue reading
1
S10 Ep21: Bagley Summarizes the ACTION trial of ONC201 in H3 K27M–Mutant Diffuse Midline Gliomas
13:40
13:40
「あとで再生する」
「あとで再生する」
リスト
気に入り
気に入った
13:40
Dr Bagley discusses the evaluation of the small molecule ONC201 in the phase 3 ACTION trial in H3 K27M–mutant diffuse midline gliomas.OncLive® On Air による
…
continue reading
1
S10 Ep20: Lunning and Herrera Highlight Frontline Hodgkin Lymphoma Management Strategies
14:13
14:13
「あとで再生する」
「あとで再生する」
リスト
気に入り
気に入った
14:13
Dr Lunning sits down with Alex Herrera, MD, of City of Hope, to discuss the frontline management of Hodgkin lymphoma, including the rationale for the SWOG 1826 trial, the collaborative efforts between pediatric and adult oncologists that led to the successful initiation of this trial, potential future directions for this research, and more.…
…
continue reading
1
S10 Ep19: FDA Approval Insights: NALIRIFOX in Metastatic Pancreatic Cancer
7:19
7:19
「あとで再生する」
「あとで再生する」
リスト
気に入り
気に入った
7:19
Dr Wainberg discusses the FDA approval of first-line NALIRIFOX for patients with metastatic pancreatic adenocarcinoma, key data from NAPOLI 3, and the potential evolution of NALIRIFOX’s role in the treatment of patients with pancreatic cancer.OncLive® On Air による
…
continue reading
1
S10 Ep18: Dr Kyriakopoulos on the Investigation of Masofaniten Plus Enzalutamide in mCRPC
11:03
11:03
「あとで再生する」
「あとで再生する」
リスト
気に入り
気に入った
11:03
Dr Kyriakopoulos sheds light on the potential synergy and pharmacokinetic interactions between masofaniten and enzalutamide when used in combination for patients with prostate cancer; contextualizes safety and pharmacokinetic findings from the phase 1 portion of a phase 1/2 study; and outlines key objectives of the agent’s ongoing evaluation in the…
…
continue reading
1
S10 Ep17: Kang Highlights Considerations for the Integration of Toripalimab into Nasopharyngeal Carcinoma Clinical Practice
8:49
8:49
「あとで再生する」
「あとで再生する」
リスト
気に入り
気に入った
8:49
Dr Kang discusses the significance of the FDA approval of toripalimab for nasopharyngeal carcinoma, his anticipated use of the agent since its inclusion on UCSF’s formulary, and the debate around Epstein-Barr virus as a selection criteria for treatment eligibility.OncLive® On Air による
…
continue reading
1
S10 Ep16: Mims Expands on the Evaluation of Emavusertib in the TakeAim Leukemia Trial of AML and MDS
10:05
10:05
「あとで再生する」
「あとで再生する」
リスト
気に入り
気に入った
10:05
Dr Mims discusses the utility of emavusertib in acute myeloid leukemia and myelodysplastic syndrome and the rationale for the TakeAim Leukemia trial.OncLive® On Air による
…
continue reading
1
S10 Ep15: Tripathy Talks Through the Enduring Impact of the Miami Breast Cancer Conference
16:24
16:24
「あとで再生する」
「あとで再生する」
リスト
気に入り
気に入った
16:24
Dr Tripathy discusses aspects of the Miami Breast Cancer Conference that stood out to him during his first time speaking at the meeting, ways that Miami Breast has evolved over the years, and the types of valuable multidisciplinary discussions that the meeting inspires.OncLive® On Air による
…
continue reading
1
S10 Ep14: Kitco and Patel Emphasize the Importance of GVHD Research and Awareness
15:57
15:57
「あとで再生する」
「あとで再生する」
リスト
気に入り
気に入った
15:57
Drs Kitko and Patel discuss graft-versus-host disease recognition, treatment selection, and ongoing research with novel agents and biomarkers of response.OncLive® On Air による
…
continue reading
1
S10 Ep13: FDA Approval Insights: Enfortumab Vedotin Plus Pembrolizumab in Locally Advanced/Metastatic Urothelial Carcinoma
9:06
9:06
「あとで再生する」
「あとで再生する」
リスト
気に入り
気に入った
9:06
Dr Galsky discusses the FDA approval of enfortumab vedotin plus pembrolizumab for patients with locally advanced or metastatic urothelial cancer, key efficacy and safety data from the EV-302 trial, and future directions in urothelial cancer research.OncLive® On Air による
…
continue reading
1
S10 Ep12: Community Oncologists on the Importance of Self-Reliance and Collegial Trust as Women in Medicine
22:06
22:06
「あとで再生する」
「あとで再生する」
リスト
気に入り
気に入った
22:06
Drs Jacob, Van Der Wall, and Wright-Browne discuss challenges related to gender bias that they have faced throughout their careers, growth opportunities that have arisen from these obstacles, and the importance of reflecting on past accomplishments and future goals.OncLive® On Air による
…
continue reading
1
S10 Ep11: Lunning and Brander Emphasize the Importance of Early CLL Diagnosis and Treatment
14:30
14:30
「あとで再生する」
「あとで再生する」
リスト
気に入り
気に入った
14:30
Drs Lunning and Brander discuss the evolution of chronic lymphocytic leukemia management.OncLive® On Air による
…
continue reading
1
S10 Ep10: Expert and Patient Perspectives on AE Management With FGFR Inhibitors in Cholangiocarcinoma
16:41
16:41
「あとで再生する」
「あとで再生する」
リスト
気に入り
気に入った
16:41
Goyal, Bishop, Kelley, and Kuhlman discuss ways to prepare patients with cholangiocarcinoma for FGFR inhibitor–related adverse effects.OncLive® On Air による
…
continue reading
1
S10 Ep9: FDA Approval Insights: Pirtobrutunib in Previously Treated CLL/SLL
10:54
10:54
「あとで再生する」
「あとで再生する」
リスト
気に入り
気に入った
10:54
Dr Davids discusses the FDA approval of pirtobrutinib for patients with previously treated CLL/SLL; key efficacy and safety data from the BRUIN trial; and guidelines for pirtobrutinib use in clinical practice in the CLL/SLL patient population.OncLive® On Air による
…
continue reading
1
S10 Ep8: Lunning and Maddocks Talk Through Frontline MCL Management
14:10
14:10
「あとで再生する」
「あとで再生する」
リスト
気に入り
気に入った
14:10
Dr Lunning sits down with Kami J. Maddocks, MD, of The Ohio State University Comprehensive Cancer Center––James, to discuss the management of MCL in the up-front setting, including practice-changing findings from the SHINE and TRIANGLE trials; how these trial data have altered the role of first-line BTK inhibitors in chemotherapy-free regimens for …
…
continue reading
1
S10 Ep7: FDA Approval Insights: Nirogacestat in Progressing Desmoid Tumors Requiring Systemic Treatment
7:21
7:21
「あとで再生する」
「あとで再生する」
リスト
気に入り
気に入った
7:21
Dr Kasper discusses the FDA approval of nirogacestat for patients with progressing desmoid tumors; key efficacy, safety, and quality-of-life outcomes from the pivotal DeFi trial; and findings from an analysis investigating tumor volume and T2 hyperintensity changes with nirogacestat in patients enrolled in DeFi.…
…
continue reading
1
S10 Ep6: Monk and Tarantino Describe the Investigation of B7-H4 Vedotin–Directed ADCs in Gynecologic and Breast Cancers
21:55
21:55
「あとで再生する」
「あとで再生する」
リスト
気に入り
気に入った
21:55
Drs Monk and Tarantino highlight current research investigating B7-H4–directed ADCs in multiple solid tumor types; other promising ADCs in development for gynecologic cancers; and future research needed to clarify unanswered questions regarding the sequencing of ADCs in breast cancer.OncLive® On Air による
…
continue reading
1
S10 Ep5: Donington and Stiles Summarize NSCLC Resectability Parameters and Multidisciplinary Management
11:54
11:54
「あとで再生する」
「あとで再生する」
リスト
気に入り
気に入った
11:54
Drs Donington and Stiles discuss the implications of perioperative immunotherapy trials on early-stage lung cancer management, definitions of resectability, and the incorporation of new guidance regarding multidisciplinary management.OncLive® On Air による
…
continue reading
1
S10 Ep4: FDA Approval Insights: Capivasertib Plus Fulvestrant in Advanced HR+/HER2- Breast Cancer With PIK3CA, AKT1, or PTEN Alterations
14:01
14:01
「あとで再生する」
「あとで再生する」
リスト
気に入り
気に入った
14:01
Dr Gradishar discusses the FDA approval of capivasertib plus fulvestrant for patients with advanced HR-positive, HER2-negative breast cancer harboring PIK3CA, AKT1, or PTEN alterations.OncLive® On Air による
…
continue reading
1
S10 Ep3: Santos Summarizes Key Updates From EMPOWER-Lung 1 and EMPOWER-Lung 3 With Cemiplimab in NSCLC
15:30
15:30
「あとで再生する」
「あとで再生する」
リスト
気に入り
気に入った
15:30
Dr Santos discusses findings from the EMPOWER-Lung 3 trial of cemiplimab plus chemotherapy in patients with advanced non–small cell lung cancer, as well as data from subgroup analyses of the EMPOWER-Lung 1 trial of cemiplimab monotherapy in patients with NSCLC and a PD-L1 score over 50%.OncLive® On Air による
…
continue reading
1
S10 Ep2: Jabbour Reports Top Takeaways From ASH 2023 of Olverembatinib in CML and ALL
8:07
8:07
「あとで再生する」
「あとで再生する」
リスト
気に入り
気に入った
8:07
Dr Jabbour discusses the activity and the utilization of olverembatinib in chronic myeloid leukemia and expanded upon the role that TKIs can play in the management of malignancies beyond chronic myeloid leukemia and acute lymphoblastic leukemia.OncLive® On Air による
…
continue reading
1
S10 Ep1: Eskander Emphasizes the Importance of Inclusivity and Accessibility in Oncology Clinical Trials
13:33
13:33
「あとで再生する」
「あとで再生する」
リスト
気に入り
気に入った
13:33
Dr Eskander discusses the impact of social determinants of health on cancer clinical trial participation; effective strategies for considering and engaging diverse communities in the clinical trial process; and how community partnerships can be strengthened to eliminate these financial and logistical barriers.…
…
continue reading
1
S9 Ep50: Lunning and Mehta-Shah Unpack Treatment Needs and Future Directions in PTCL
17:26
17:26
「あとで再生する」
「あとで再生する」
リスト
気に入り
気に入った
17:26
Dr Lunning and Neha Mehta-Shah, MD, MSCI, of Washington University School of Medicine, highlight challenges that arise when diagnosing patients with PTCL; how molecular testing results influence induction and consolidation treatment approaches for patients with ALK-negative anaplastic large cell lymphoma; and novel frontline agents under investigat…
…
continue reading
1
S9 Ep49: Simeone and Fakih Detail Research Objectives With A2B530 in CEA-Expressing Solid Tumors
25:10
25:10
「あとで再生する」
「あとで再生する」
リスト
気に入り
気に入った
25:10
Drs Simeone and Fakih discuss the main objective and design of the observational BASECAMP-1 study and how it functions alongside the EVEREST-1 study, which is evaluating the autologous CAR T-cell therapy A2B530 in patients with CEA-expressing solid tumors that have lost HLA-A*02 expression.OncLive® On Air による
…
continue reading
1
S9 Ep48: Donington and Stiles Describe the Surgical Implications of Lung Cancer Treatment Evolutions
11:24
11:24
「あとで再生する」
「あとで再生する」
リスト
気に入り
気に入った
11:24
Drs Donington and Stiles discuss how the findings from the ADAURA trial with adjuvant osimertinib have changed thoracic surgery expectations, the potential surgical implications of the ALINA trial with adjuvant alectinib, and the importance of early-stage molecular testing in lung cancer.OncLive® On Air による
…
continue reading
1
S9 Ep47: Abdou Spotlights Factors Influencing ADC Treatment Selection in Breast Cancer
14:34
14:34
「あとで再生する」
「あとで再生する」
リスト
気に入り
気に入った
14:34
Dr Abdou discusses how characteristics of patients with breast cancer impact ADC treatment selection and highlights some of the topline takeaways from breast cancer treatment to come out of the 2023 ASCO Annual Meeting.OncLive® On Air による
…
continue reading
1
S9 Ep46: FDA Approval Insights: Toripalimab in Recurrent/Metastatic Nasopharyngeal Carcinoma
17:17
17:17
「あとで再生する」
「あとで再生する」
リスト
気に入り
気に入った
17:17
Drs Hanna and Kandula discuss the significance of the FDA approval of toripalimab in nasopharyngeal carcinoma; pivotal data from the JUPITER-02 and POLARIS-02 trials; and how the addition of toripalimab to the nasopharyngeal carcinoma treatment armamentarium increases the importance of multidisciplinary collaboration.…
…
continue reading
1
S9 Ep45: Lunning and Jacobson Dissect the Role of CAR T-Cell Therapy in Follicular Lymphoma
15:27
15:27
「あとで再生する」
「あとで再生する」
リスト
気に入り
気に入った
15:27
Dr Lunning sits down with Caron A. Jacobson, MD, MMSc, or Dana-Farber Cancer Institute, to discuss the characteristics of FL that may prompt aggressive treatment, the potential optimal role of CAR T-cell therapy in the third line and beyond, and how the toxicity profiles of different CAR T-cell products compare with each other.…
…
continue reading
1
S9 Ep44: Dumbrava Details Ongoing Research With PC14586 in p53 Y220C–Mutated Advanced Solid Tumors
10:48
10:48
「あとで再生する」
「あとで再生する」
リスト
気に入り
気に入った
10:48
Dr Dumbrava discusses the rationale and design of the PYNNACLE trial; phase 1 efficacy and safety findings with PC14586 in patients with p53 Y220C–mutated advanced solid tumors; and the next steps for this research.OncLive® On Air による
…
continue reading
1
S9 Ep43: FDA Approval Insights: Ivosidenib in R/R IDH1+ Myelodysplastic Syndrome
8:27
8:27
「あとで再生する」
「あとで再生する」
リスト
気に入り
気に入った
8:27
Dr DiNardo discusses the the FDA approval of ivosidenib for patients with relapsed/refractory IDH1-mutant myelodysplastic syndromes, the unique mechanism of action of ivosidenib, and key efficacy and safety findings from the AG120-C-001 trial.OncLive® On Air による
…
continue reading
1
S9 Ep42: Halmos Highlights Evaluation of the EGFR Inhibitor BDTX-1535 in NSCLC
13:07
13:07
「あとで再生する」
「あとで再生する」
リスト
気に入り
気に入った
13:07
Dr Halmos discusses the ongoing investigation of the potent, selective, and irreversible EGFR inhibitor BDTX-1535 in patients with non–small cell lung cancer.OncLive® On Air による
…
continue reading
1
S9 Ep41: Feigin Discusses the Association Between Benzodiazepines and Pancreatic Cancer Outcomes
11:57
11:57
「あとで再生する」
「あとで再生する」
リスト
気に入り
気に入った
11:57
Dr Feigin discusses findings from a study on the varying effects of the benzodiazepines lorazepam and alprazolam on PFS outcomes for patients with pancreatic cancer.OncLive® On Air による
…
continue reading
1
S9 Ep40: Khouri Highlights the Ongoing AFFIRM-AL Trial in AL Amyloidosis
13:09
13:09
「あとで再生する」
「あとで再生する」
リスト
気に入り
気に入った
13:09
Dr Khouri discusses unmet needs in AL amyloidosis, the potential for birtamimab to become a new frontline standard of care beyond daratumumab, and the importance of confirming earlier post-hoc results from the placebo-controlled phase 3 VITAL trial in the ongoing AFFIRM-AL trial in patients with Mayo stage IV AL amyloidosis with cardiac involvement…
…
continue reading
1
S9 Ep39: FDA Approval Insights: Adjuvant Nivolumab in Completely Resected Stage IIB/C Melanoma
11:46
11:46
「あとで再生する」
「あとで再生する」
リスト
気に入り
気に入った
11:46
Dr Weber discusses the FDA approval of adjuvant nivolumab for patients with completely resected stage IIB/C melanoma, key efficacy data from the CheckMate76K trial, and potential future directions for PD-1 inhibitor–based combinations in the melanoma treatment paradigm.OncLive® On Air による
…
continue reading
1
S9 Ep38: Lunning and Nastoupil Highlight Treatment Considerations and Ongoing Research in Follicular Lymphoma
15:12
15:12
「あとで再生する」
「あとで再生する」
リスト
気に入り
気に入った
15:12
Drs Lunning and Nastoupil discuss the ins and outs of diagnostic workups for patients with follicular lymphoma; how to discern which patients may benefit most from standard chemotherapy vs clinical trial regimens in the frontline setting; and ongoing follicular lymphoma research that may alter the treatment paradigm.…
…
continue reading
1
S9 Ep37: Naumann Discusses Notable Research Efforts in Endometrial Cancer
7:15
7:15
「あとで再生する」
「あとで再生する」
リスト
気に入り
気に入った
7:15
Dr Naumann discusses the role of frontline maintenance therapy for patients with endometrial cancer; which patients are likely to benefit from the RUBY and NRG-GY018 trial regimens; and ongoing research that may elucidate optimal treatments for patients with recurrent, dMMR disease.OncLive® On Air による
…
continue reading
1
S9 Ep36: Keshava Emphasizes the Importance of Lung Nodule Programs for Early Lung Cancer Detection
9:52
9:52
「あとで再生する」
「あとで再生する」
リスト
気に入り
気に入った
9:52
Dr Keshava discusses the rationale behind lung nodule programs, common barriers to implementing these programs, and how multidisciplinary collaboration can lead to successful early lung cancer diagnoses.OncLive® On Air による
…
continue reading
1
S9 Ep35: Hasanuma Highlights the Benefits of Building Authentic Connections Through Mentorship
16:04
16:04
「あとで再生する」
「あとで再生する」
リスト
気に入り
気に入った
16:04
Dr Hasunuma shares that the objective of mentorship is to foster care, trust, and respect in mentor-mentee relationships and create authentic connections.OncLive® On Air による
…
continue reading
1
S9 Ep34: FDA Approval Insights: Momelotinib in Myelofibrosis With Anemia
12:00
12:00
「あとで再生する」
「あとで再生する」
リスト
気に入り
気に入った
12:00
Dr Kuykendall discusses the FDA approval of momelotinib in myelofibrosis with anemia, key data from the MOMENTUM trial, and how momelotinib alters the myelofibrosis treatment paradigm.OncLive® On Air による
…
continue reading
1
S9 Ep33: Gutierrez and Leslie Discuss Recent Efforts and Future Advances in CAR T-Cell Therapy
15:13
15:13
「あとで再生する」
「あとで再生する」
リスト
気に入り
気に入った
15:13
Drs Gutierrez and Leslie discuss common barriers that institutions face when implementing CAR T-cell therapy programs, the early success story of outpatient administration of this modality at John Theurer Cancer Center, and future considerations for using this treatment approach in solid tumors.OncLive® On Air による
…
continue reading
1
S9 Ep32: Expert Insights on the United States Chemotherapy Shortage
15:29
15:29
「あとで再生する」
「あとで再生する」
リスト
気に入り
気に入った
15:29
Oncology experts discuss the platinum chemotherapy shortage in the United States.OncLive® On Air による
…
continue reading
1
S9 Ep31: FDA Approval Insights: First-Line Luspatercept for Anemia in Lower-Risk MDS
10:47
10:47
「あとで再生する」
「あとで再生する」
リスト
気に入り
気に入った
10:47
Dr Platzbecker discusses the FDA approval of luspatercept in lower-risk MDS with anemia; key efficacy and safety data from the COMMANDS trial; and how this approval addresses historically unmet needs for patients with MDS.OncLive® On Air による
…
continue reading
1
S9 Ep30: Richardson Reviews Findings and Future Directions With Mezigdomide Plus Dexamethasone in R/R Myeloma
24:39
24:39
「あとで再生する」
「あとで再生する」
リスト
気に入り
気に入った
24:39
Dr Richardson discusses the background of mezigdomide, key efficacy and safety findings with the agent plus dexamethasone in patients with relapsed/refractory multiple myeloma, and the implications of this combination for heavily pretreated patients in this population.OncLive® On Air による
…
continue reading
1
S9 Ep29: Garcia-Manero and Zeidan Highlight Key Implications of the COMMANDS Trial in Lower-Risk MDS
30:16
30:16
「あとで再生する」
「あとで再生する」
リスト
気に入り
気に入った
30:16
Drs Garcia-Manero and Zeidan discuss the significance of efficacy and safety data from the COMMANDS trial in MDS, takeaways from the subgroup analyses, and expectations around treatment sequencing in the lower-risk MDS population.OncLive® On Air による
…
continue reading
1
S9 Ep28: FDA Approval Insights: Elranatamab in Relapsed/Refractory Multiple Myeloma
18:34
18:34
「あとで再生する」
「あとで再生する」
リスト
気に入り
気に入った
18:34
Dr Nooka discusses the FDA approval of elranatamab in relapsed/refractory multiple myeloma, key data from MagnetisMM-3, and the evolving role of bispecific antibodies in the multiple myeloma treatment paradigm.OncLive® On Air による
…
continue reading